跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CAR-NK-CD19
首页
药物
CAR-NK-CD19
CAR-NK-CD19
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF IN IMMUNOTHERAPY
EP 3773918 A1
申请人: NKARTA INC
优先权: 2019
CN
EP
US
WO
14 件公开
ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLS
EP 3743512 A4
申请人: NANTKWEST INC
优先权: 2018
CN
EP
US
8 件公开
CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
EP 4065157 A1
申请人: NOVARTIS AG
优先权: 2019
CN
EP
US
6 件公开
METHODS FOR TREATMENT OF AUTOIMMUNE DISEASES
EP 4687965 A1
申请人: NKARTA INC
优先权: 2023
CN
EP
US
WO
4 件公开
ANTIBODY BINDING TO CD22, AND BISPECIFIC ANTIBODY, CHIMERIC ANTIGEN RECEPTOR AND ANTIBODY-DRUG CONJUGATE COMPRISING SAME, AND USE THEREOF
EP 4613770 A1
申请人: ASAN FOUND
优先权: 2022
EP
US
WO
3 件公开
METHODS FOR CD48 TARGETED IMMUNOTHERAPY
EP 4658300 A2
申请人: YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD
优先权: 2023
EP
US
WO
3 件公开
INHIBITORY CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF
US 20260115290 A1
申请人: UNIV OF SOUTHERN CALIFORNIA
优先权: 2021
US
WO
2 件公开
NUCLEIC ACID SEQUENCE ENCODING A CHIMERIC ANTIGEN NATURAL KILLER CELL RECEPTOR (NK-CAR), POLYPEPTIDE OF SAID NK-CAR, VECTOR COMPRISING SAID NUCLEIC ACID SEQUENCE, IN VITRO METHOD OF OBTAINING AN NK CELL, USE OF SAID NUCLEIC ACID SEQUENCE, POLYPEPTIDE OR VECTOR, AND PHARMACEUTICAL COMPOSITION
EP 4516311 A1
申请人: FUND HEMOCENTRO DE RIBEIRAO PRETO
优先权: 2022
EP
US
2 件公开
CD19 CAR NK CELLS FOR USE IN METHODS OF TREATING CANCER
US 20250186587 A1
申请人: TAKEDA PHARMACEUTICALS CO
优先权: 2022
CN
US
2 件公开
ENRICHED T-CELL POPULATIONS
EP 4784729 A1
申请人: CLEVELAND CLINIC FOUND
优先权: 2023
EP
WO
2 件公开
第 1 / 5 页
上一页
下一页
药物
反馈